What is NCT05512345 related to Apraclonidine?
NCT05512345 is a clinical trial investigating apraclonidine's effectiveness in preventing or treating intraocular pressure (IOP) spikes after laser iridotomy. Apraclonidine is a medication used to lower IOP [1]. The trial is a randomized, double-blind, placebo-controlled study with two arms. Participants receive either apraclonidine 0.5% eye drops or a placebo [1]. The primary outcome is the incidence of IOP spikes within 24 hours post-procedure, defined as an increase of 5 mmHg or more from baseline IOP [1].
Who is conducting this study?
The study is sponsored by The University of California, San Francisco [1].
When is this study expected to be completed?
The study's estimated completion date is December 1, 2024 [1].
What are the eligibility criteria for participants?
To be eligible, participants must be at least 18 years old and have undergone or be scheduled for laser iridotomy. They must also have a baseline IOP of 21 mmHg or lower [1].
Why is controlling IOP after laser iridotomy important?
Laser iridotomy is a procedure to treat or prevent angle-closure glaucoma by creating a small opening in the iris. A temporary increase in IOP, known as a post-laser IOP spike, can occur after this procedure. If left unmanaged, these spikes can potentially be harmful to the optic nerve. This study aims to determine if apraclonidine can effectively prevent these spikes [1].
How does Apraclonidine work to lower eye pressure?
Apraclonidine is an alpha-adrenergic agonist. It works by decreasing the production of aqueous humor, the fluid inside the eye, and potentially increasing its outflow, both of which contribute to lowering intraocular pressure [2].
Are there other medications used to manage post-laser IOP spikes?
While apraclonidine is being investigated in NCT05512345, other medications like brimonidine are also alpha-adrenergic agonists and have been used to manage IOP. The choice of medication and its efficacy can depend on individual patient factors and physician preference [2].
What are the potential risks or side effects of Apraclonidine?
Common side effects of apraclonidine eye drops can include redness, burning, or stinging of the eye. Systemic side effects, though less common, can include dry mouth, fatigue, or dizziness [2]. The trial protocol for NCT05512345 closely monitors for adverse events [1].
What is the patent status of Apraclonidine?
Apraclonidine has been available for some time and is a well-established medication. Patents related to the original discovery and formulation of apraclonidine have likely expired. However, there can be new patents related to specific delivery methods, combination therapies, or new indications for the drug. For detailed patent information, resources like DrugPatentWatch.com can provide current data on patent expiry and status [3].